Ekso Bionics (EKSO) Receives Coverage Optimism Score of 0.15
Media coverage about Ekso Bionics (NASDAQ:EKSO) has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ekso Bionics earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.1535451189228 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Ekso Bionics Holdings, Inc. (EKSO) Grabs Dynamic Performance Momentum on Volatility – Stock News Stop (stockmarketstop.com)
- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Eye-Catching Hot Stocks – Nasdaq Journal (press release) (nasdaqjournal.com)
- ETFs with exposure to Ekso Bionics Holdings, Inc. : December 7, 2017 (finance.yahoo.com)
- Explored in latest research Medical Bionic Implant Market Size & Share, Growth, Trends, and Forecast 2017 – 2025 (mynewsdesk.com)
- Market Size For Medical Robotic System: Global Industry Size, Share, Trends and Forecast, 2014 – 2024 by Acumen Research and Consulting (medgadget.com)
Shares of Ekso Bionics (NASDAQ EKSO) traded up $0.03 during mid-day trading on Friday, hitting $2.75. 637,561 shares of the stock traded hands, compared to its average volume of 5,571,405. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.73 and a current ratio of 6.09. Ekso Bionics has a 1 year low of $0.99 and a 1 year high of $4.77.
Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million. Ekso Bionics had a negative net margin of 343.53% and a negative return on equity of 323.00%. analysts forecast that Ekso Bionics will post -0.81 earnings per share for the current year.
Several equities research analysts have issued reports on EKSO shares. Zacks Investment Research raised shares of Ekso Bionics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Thursday, September 7th. ValuEngine raised shares of Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th.
In other news, insider Russ Angold sold 50,000 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total transaction of $175,500.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.32% of the company’s stock.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.